VANCOUVER, Sept. 21 /CNW/ - Burcon NutraScience Corporation (TSX - BU) ("Burcon" or the "Corporation") is pleased to announce today that it has received a notice of allowance from the United States Patent and Trademark Office for a patent application covering the overall production process and general processing conditions for producing Burcon's Supertein(TM) canola protein isolate.
Supertein(TM) is a highly-soluble napin-rich canola protein isolate comprised principally of albumin proteins. The functional properties of Supertein(TM) include excellent solubility, the ability to form transparent solutions, foaming and nutrition. Applications for Supertein(TM) include beverages, confectionery, aerated desserts, and protein bars, among others.
"This most recent notice of allowance from the United States Patent and Trademark Office is commercially significant as it covers an important patent application for producing Supertein(TM)," said Johann F. Tergesen, President and Chief Operating Officer, adding, "Supertein(TM) is unique for both its nutritional and functional characteristics. Functionally, it has exceptional solubility and nutritionally, Supertein(TM) has an amino acid profile which is particularly rich in cysteine."
To-date, Burcon's patent portfolio consists of 92 issued patents in various countries, including 8 issued U.S. patents, and in excess of 200 additional pending patent applications, 70 of which are U.S. patent applications. Two of the 70 U.S. patent applications have now been allowed, including the patent allowance which is the subject of this news release, and will be issued as granted U.S. patents in the near future.
About Burcon NutraScience
Burcon is a leader in nutrition, health and wellness in the field of functional, renewable plant proteins. Since 1999, Burcon has developed a portfolio of composition, application, and process patents originating from our core protein extraction and purification technology. We are developing the world's first commercial canola proteins, Puratein(R) and Supertein(TM) with unique functional and nutritional attributes, and CLARISOY(TM), a revolutionary soy protein isolate which is 100% soluble and completely transparent in acidic solutions. Our team of highly specialized scientists and engineers work from our own research facility to develop and optimize environmentally sound technologies. To-date, our patent portfolio consists of 92 issued patents in various countries, including 8 issued U.S. patents, and in excess of 200 additional pending patent applications, 70 of which are U.S. patent applications.
ON BEHALF OF THE BOARD OF DIRECTORS
"Johann F. Tergesen"
Johann F. Tergesen
Burcon NutraScience Corporation is a publicly listed on the Toronto Stock
Exchange under the symbol "BU". For more information on Burcon, visit
This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, the Corporation's, plans and timing for the introduction or enhancement of our products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations regarding the prospect for future success depend upon our ability to develop and sell products, which we do not produce today and cannot be sold without further research and development. When used in this press release, the words "goal", "intend", "believes", "potential", "expected", "anticipates", "will be", and similar expressions, generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties. In light of the many risks and uncertainties surrounding the development of a source of protein from canola meal, you should understand that we cannot assure you that the forward looking statements contained in this press release will be realized.
SOURCE Burcon NutraScience Corporation
For further information: For further information: Jade Cheng, Chief Financial Officer, Burcon NutraScience Corporation, (604) 733-0896, (888) 408-7960 toll-free, email@example.com, www.burcon.ca; AXINO AG, Wolfgang Seybold, Investor Relations Europe, AXINO AG, Konigstrasse 26, 70173, Stuttgart, Germany, Tel. +49-711-25 35 92-40, Fax +49-711-25 35 92-55, firstname.lastname@example.org www.burcon.net